Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze

Sela, Vânia Ramos; Biesdorf, Carla; Ramos, Diego Henrique; Zangrossi, Hélio; Graeff, Frederico Guilherme; Audi, Elisabeth Aparecida

doi:10.1016/j.neulet.2011.03.040

Cited by 13 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The dorsal gray matter, particularly the dorsal division, is a key station in the integration of emotional processing of aversive stimuli (i.e., fear and panic responses) and nociception [55]–[56], where sensory and stress information elicits fight or flight reactions. The dorsal gray matter also contains neurons that respond to major stress hormones [57], and direct pharmacological manipulations with drugs affecting serotonin transmission [55]–[56], [58]–[59], GABAergic receptors [60], CRF inputs [61] or BDNF signaling [62] that result in anxiolytic or panicolytic responses. It remains unknown whether the LPA modulates these transmitter systems, as the only available evidence relies on the neurochemical abnormalities described in LPA 1 -null mice [63]–[64].…”

Section: Discussionmentioning

confidence: 99%

1-Oleoyl Lysophosphatidic Acid: A New Mediator of Emotional Behavior in Rats

et al. 2014

View full text Add to dashboard Cite

The role of lysophosphatidic acid (LPA) in the control of emotional behavior remains to be determined. We analyzed the effects of the central administration of 1-oleoyl-LPA (LPA 18∶1) in rats tested for food consumption and anxiety-like and depression-like behaviors. For this purpose, the elevated plus-maze, open field, Y maze, forced swimming and food intake tests were performed. In addition, c-Fos expression in the dorsal periaqueductal gray matter (DPAG) was also determined. The results revealed that the administration of LPA 18∶1 reduced the time in the open arms of the elevated plus-maze and induced hypolocomotion in the open field, suggesting an anxiogenic-like phenotype. Interestingly, these effects were present following LPA 18∶1 infusion under conditions of novelty but not under habituation conditions. In the forced swimming test, the administration of LPA 18∶1 dose-dependently increased depression-like behavior, as evaluated according to immobility time. LPA treatment induced no effects on feeding. However, the immunohistochemical analysis revealed that LPA 18∶1 increased c-Fos expression in the DPAG. The abundant expression of the LPA1 receptor, one of the main targets for LPA 18∶1, was detected in this brain area, which participates in the control of emotional behavior, using immunocytochemistry. These findings indicate that LPA is a relevant transmitter potentially involved in normal and pathological emotional responses, including anxiety and depression.

show abstract

Section: Discussionmentioning

confidence: 99%

1-Oleoyl Lysophosphatidic Acid: A New Mediator of Emotional Behavior in Rats

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Rats treated with this pindolol-paroxetine combination show increased escape latencies in the elevated T-maze, a panicolytic effect, which is blocked by pretreatment with the 5-HT 1A receptor antagonist, WAY-100635 (Sela et al, 2011). Another model revealed that DPAG-evoked flight behaviors (e.g., galloping) are sensitive to the actions of panicolytic and panicogenic drugs, with these drugs reducing and facilitating DPAG-evoked behaviors, respectively (Schenberg et al, 2001).…”

Section: A Putative Panic Inhibition System Involving the Amygdalamentioning

confidence: 99%

The Deakin/Graeff hypothesis: Focus on serotonergic inhibition of panic

Paul

Johnson

Shekhar

et al. 2014

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

The Deakin/Graeff hypothesis proposes that different subpopulations of serotonergic neurons through topographically organized projections to forebrain and brainstem structures modulate the response to acute and chronic stressors, and that dysfunction of these neurons increases vulnerability to affective and anxiety disorders, including Panic Disorder. We outline evidence supporting the existence of a serotonergic system originally discussed by Deakin/Graeff that is implicated in the inhibition of panic-like behavioral and physiological responses. Evidence supporting this panic inhibition system comes from the following observations: 1) serotonergic neurons located in the ‘ventrolateral dorsal raphe nucleus (DRVL) as well as the ventrolateral periaqueductal gray (VLPAG) inhibit dorsal periaqueductal gray-elicited panic-like responses; 2) chronic, but not acute, antidepressant treatment potentiates serotonin’s panicolytic effect; 3) contextual fear activates a central nucleus of the amygdala-DRVL/VLPAG circuit implicated in mediating freezing and inhibiting panic-like escape behaviors; 4) DRVL/VLPAG serotonergic neurons are central chemoreceptors and modulate the behavioral and cardiorespiratory response to panicogenic agents such as sodium lactate and CO2. Implications of the panic inhibition system are discussed.

show abstract

“…It was reported that 5-HT 1A/1B −/− mice induced a strong anxious-like behavioral state [18]. The 5-HT 1A receptor antagonist pindolol had been combined with SSRIs in patients with anxiety disorders to shorten the onset of the clinical action and increase the proportion of responders [19]. It was believed that serotonergic negative feedback mediated by 5-HT 1A autoreceptors to decrease the synthesis and release of 5-HT after SSRI medication was associated with the delayed therapeutic effect [20–22].…”

Section: Discussionmentioning

confidence: 99%

Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study

Song

Liu

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine-diazepam, or paroxetine-MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self-Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine-MSZRT and paroxetine-diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine-MSZRT as well as paroxetine-diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks' treatment, the overall effectiveness rate in the paroxetine-MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine-diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.

show abstract

Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze

Cited by 13 publications

References 34 publications

1-Oleoyl Lysophosphatidic Acid: A New Mediator of Emotional Behavior in Rats

1-Oleoyl Lysophosphatidic Acid: A New Mediator of Emotional Behavior in Rats

The Deakin/Graeff hypothesis: Focus on serotonergic inhibition of panic

Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study

Contact Info

Product

Resources

About